AEGM Stock Price, News & Analysis

AEGM is associated on Stock Titan with Aethlon Medical, Inc., a clinical-stage medical device company. According to available information, Aethlon Medical is headquartered in San Diego, California and focuses on developing the Hemopurifier®, an investigational device intended to address unmet needs in oncology and infectious disease. The company’s approach centers on selectively removing pathogenic targets from biologic fluids.

The Hemopurifier is described as an investigational medical device designed to remove enveloped viruses, fragments of viruses, and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viral proteins. EVs released by solid tumors are believed to play a role in metastasis and resistance to immunotherapies and chemotherapy, and removal of enveloped viruses, viral fragments, and EVs has been demonstrated in both in vitro studies and in human patients.

The Hemopurifier holds a U.S. Food and Drug Administration Breakthrough Device Designation for two indications: the treatment of individuals with advanced or metastatic cancer that are unresponsive to or intolerant of standard-of-care therapy, and the treatment of life-threatening viruses that are not addressed with approved therapies. These designations highlight the device’s intended role in serious disease settings where existing treatment options are limited.

Aethlon Medical has also reported building an intellectual property portfolio around the Hemopurifier. The company announced that U.S. Patent No. 12,409,260, directed to treatment of Long COVID, is intended to protect the use of the Hemopurifier in the United States for patients who have reduced COVID-19 viral load but continue to exhibit Long COVID symptoms for more than 12 weeks after infection, including treatment by removal of circulating COVID-19 spike protein. In addition, Unitary European Patent 4136453 is intended to protect use of the Hemopurifier for patients who lack circulating COVID-19 viral particles but exhibit COVID-19-associated coagulopathy (CAC).

According to company statements, the Hemopurifier remains in the research and development stage for Long COVID applications. The patent issuances are described as expanding and strengthening the intellectual property position in areas of significant unmet medical need and as part of efforts to build a foundation that could support potential future treatment options for patients. Overall, the available information characterizes Aethlon Medical as a clinical-stage developer of a blood-purification platform targeting cancer-related extracellular vesicles and life‑threatening viral pathogens.